UNH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
UnitedHealth Group Inc (UNH) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant headwinds, including weak financial performance, negative sentiment from Congress trading data, and declining analyst price targets. While the company has a strong revenue growth rate, its net income and EPS have plummeted, raising concerns about profitability. Additionally, there are no strong technical or proprietary trading signals indicating a buy opportunity at this time.
The MACD is positive but contracting, indicating weakening momentum. The RSI is neutral at 46.61, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 284.785, with resistance at 293.765 and support at 275.804. Overall, the technical indicators suggest a lack of strong upward momentum.
The company's revenue increased by 13.11% YoY in Q4 2025, showing strong top-line growth. Additionally, the company plans to use proceeds from securities sales for debt refinancing and stock buybacks, which could potentially support the stock price in the long term.
Net income and EPS have dropped significantly, down 99.82% and 99.83% YoY, respectively, raising concerns about profitability. The medical care ratio has increased, leading to higher costs and eroding investor confidence. Congress trading data shows 3 sale transactions with no purchases, indicating a cautious stance. Analyst price targets have been consistently lowered, reflecting reduced confidence in the stock's near-term performance.
In Q4 2025, revenue increased to $113.215 billion, up 13.11% YoY. However, net income dropped to $10 million, a 99.82% decline YoY, and EPS fell to $0.01, down 99.83% YoY. This indicates significant profitability challenges despite strong revenue growth.
Analysts have lowered their price targets across the board, with targets now ranging from $327 to $440. While most analysts maintain Buy or Overweight ratings, the lowered targets reflect reduced confidence in the stock's near-term performance due to earnings recovery delays and higher costs.
